Muscular Dystrophy - Wu Stem Cells Medical Center - A Leading Medical Center for Stem Cell Therapy

| All Others

eg.stem cell, stem cell treatment

Muscular dystrophy (MD) refers to a group of hereditary muscle diseases that weaken the muscles that move the human body. Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue. Nine diseases including Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss are always classified as muscular dystrophy.

[News] T��4 Increases Skeletal Muscle And May Treat Duchenne Muscular Dystrophy

[News] Gene Responsible for Duchenne Muscular Dystrophy Can Be Repaired

Researchers from Universit�� Laval's Faculty of Medicine and the CHUQ Research Center have shown that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy.

[News] Chemical That May Protect Hearts of Muscular Dystrophy Patients Discovered
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.

[News] New Therapy Substitutes Missing Protein In Those With Muscular Dystrophy
Researchers at the University of Minnesota Medical School have discovered a new therapy that shows potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.

[News] Muscular Dystrophy Association Partnership With ALS Therapy Development Ins
Muscular Dystrophy Association Renews Partnership With ALS Therapy Development Institute To Develop New Treatments For Lou Gehrig's Disease

[News] Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patient
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.

[News] Acceleron Pharma Receives FDA Orphan Designation For ACE-031 For The Treatment Of Duchenne Muscular Dystrophy
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.

[Case Analysis] Stem Cell Therapy for Progressive Muscular Dystrophy (July 20, 2009) Drs. Wu, Wang and Xu

The patient is a 6-year-old male. He was presented with progressive, aggravated and incapacitation of all four limbs for the past 3 years.

[Research & Advances] Inflammation clue to fragile bones in muscular dystrophy
Inflammation could contribute to bone loss in Duchenne's muscular dystrophy (DMD), a discovery made by a group of Italian researchers. Dr Anna Rufo and her colleagues found that levels of an inflammatory molecule, known as IL-6, are high in patients with DMD.

[Research & Advances] Broad Therapy For Muscular Dystrophy

[Research & Advances] Muscular Dystrophy: New Drug Promises Benefit Without Risk Of Infection

[Research & Advances] Progress Made Toward Early Identification Of Muscular Dystrophy

[Research & Advances] 'Jekyll and Hyde' Cell May Hold Key to Muscular Dystrophy, Fibrosis Treatme

[Research & Advances] Gene therapy for muscular dystrophy shows promise beyond safety
Researchers have cleared a safety hurdle in efforts to develop a gene therapy for a form of muscular dystrophy that disables patients by gradually weakening muscles near the hips and shoulders.

[Research & Advances] Researchers Trace Effects of Genetic Defect in Myotonic Muscular Dystrophy
Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins. A study published in Nature Structural & Molecular Biology shows that the loss of a single protein accounts for most of the molecular abnormalities associated with the disease, while loss of a second protein also seems to play an important role.

[Treatment we offer] Muscular dystrophy